Attrition from HIV testing to antiretroviral therapy initiation among patients newly diagnosed with HIV in Haiti

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages

  Noel, Edva ^a   Esperance, Morgan ^b   Mclaughlin, Megan ^b   Bertrand, Rachel ^a   Devieux, Jessy ^c   Severe, Patrice ^a   Decome, Diessy ^a   Marcelin, Adias ^a   Nicotera, Janet ^d   Delcher, Chris ^e   Griswold, Mark ^e   Meredith, Genevive ^e   Pape, Jean William ^a,f   Koenig, Serena P ^b  

^a Department of Adolescent Medicine   (Haïti)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e NATIONAL ALLIANCE OF STATE AND TERRITORIAL AIDS DIRECTORS   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Attrition; Haiti; HIV; HIV AIDS; Loss to follow up; Resource poor setting; Retention in care

Indexed keywords

ADULT; ARTICLE; CALCULATION; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; FEMALE; HAITI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 85027953235     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318281e772     Document Type: Article

References (71)

1. Tuboi SH, Schechter M, McGowan CC, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr. 2009;51:615-623.
2. Keiser O, Anastos K, Schechter M, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health. 2008;13:870-879.
3. Wolff MJ, Cortes CP, Shepherd BE, et al. Long-term outcomes of a national expanded access program to antiretroviral therapy: the Chilean AIDS cohort. J Acquir Immune Defic Syndr. 2010;55:368-374.
4. Thai S, Koole O, Un P, et al. Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Trop Med Int Health. 2009;14:1048-1058.
5. Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10, 000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS. 2008;22:873-882.
6. Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIVinfected patients in Cambodia. AIDS. 2007;21:351-359.
7. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS. 2010;24:563-572.
8. Nglazi MD, Lawn SD, Kaplan R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011; 56:e1-e8.
9. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet. 2010;376:449-457.
10. Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296:782-793.
11. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviraltreated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis. 2009;48:115-122.
12. Lima VD, Johnston K, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. 2008;198:59-67.
13. Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367:817-824.
14. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40:96-101.
15. Assefa Y, Van Damme W, Mariam DH, et al. Toward universal access to HIV counseling and testing and antiretroviral treatment in Ethiopia: looking beyond HIV testing and ART initiation. AIDS Patient Care STDS. 2010;24:521-525.
16. Mulissa Z, Jerene D, Lindtjorn B. Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. PLoS One. 2010;5:e13268.
17. Bernahu A. Confirmed referral for pre-ART and ART services: best practices from USAID/PSP-Ethiopia mobile HIV counseling and testing. In: HIV Implementers Conference; June 10-14, 2009; Windhoek, Namibia. Abstract 1462.
18. Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007;12:687-694.
19. Micek MA, Gimbel-Sherr K, Baptista AJ, et al. Loss to follow-up of adults in public HIV care systems in central Mozambique: identifying obstacles to treatment. J Acquir Immune Defic Syndr. 2009;52:397-405.
20. Tayler-Smith K, Zachariah R, Massaquoi M, et al. Unacceptable attrition among WHO stages 1 and 2 patients in a hospital-based setting in rural Malawi: can we retain such patients within the general health system? Trans R Soc Trop Med Hyg. 2010;104:313-319.
21. Zachariah R, Harries AD, Manzi M, et al. Acceptance of anti-retroviral therapy among patients infected with HIV and tuberculosis in rural Malawi is low and associated with cost of transport. PLoS One. 2006;1:e121.
22. April MD, Walensky RP, Chang Y, et al. HIV testing rates and outcomes in a South African community, 2001-2006: implications for expanded screening policies. J Acquir Immune Defic Syndr. 2009;51:310-316.
23. Bassett IV, Regan S, Chetty S, et al. Who starts antiretroviral therapy in Durban, South Africa? Not everyone who should. AIDS. 2010;24(suppl 1): S37-S44.
24. Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr. 2009;51:135-139.
25. Kaplan R, Orrell C, Zwane E, et al. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS. 2008;22:1679-1681.
26. Ingle SM, May M, Uebel K, et al. Outcomes in patients waiting for antiretroviral treatment in the Free State Province, South Africa: prospective linkage study. AIDS. 2010;24:2717-2725.
27. Kranzer K, Zeinecker J, Ginsberg P, et al. Linkage to HIV care and antiretroviral therapy in Cape Town, South Africa. PLoS One. 2010;5:e13801.
28. Larson BA, Brennan A, McNamara L, et al. Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ. 2010;88:675-680.
29. Larson BA, Brennan A, McNamara L, et al. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010;15(suppl 1):43-47.
30. Lawn SD, Myer L, Harling G, et al. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43:770-776.
31. Lessells RJ, Mutevedzi PC, Cooke GS, et al. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu- Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56:e79-e86.
32. Losina E, Bassett IV, Giddy J, et al. The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One. 2010;5:e9538.
33. Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290.
34. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148.
35. McGrath N, Glynn JR, Saul J, et al. What happens to ART-eligible patients who do not start ART? Dropout between screening and ART initiation: a cohort study in Karonga, Malawi. BMC Public Health. 2010;10:601.
36. van Griensven J, Sopheak T, Aseffa Y, et al. Attrition of HIV-infected individuals not yet eligible for antiretroviral treatment: do we care? Trans R Soc Trop Med Hyg. 2010;104:690-692; author reply 2-3.
37. Pepper DJ, Marais S, Wilkinson RJ, et al. Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa. PLoS One. 2011;6: e19484.
38. McGuire M, Munyenyembe T, Szumilin E, et al. Vital status of pre-ART and ART patients defaulting from care in rural Malawi. Trop Med Int Health. 2010;15(suppl 1):55-62.
39. Zachariah R, Tayler-Smith K, Manzi M, et al. Retention and attrition during the preparation phase and after start of antiretroviral treatment in Thyolo, Malawi, and Kibera, Kenya: implications for programmes? Trans R Soc Trop Med Hyg. 2011;105:421-430.
40. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med 2011;8:e1001056.
41. Koenig SP, Rodriguez LA, Bartholomew C, et al. Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. J Acquir Immune Defic Syndr. 2012;59:e60-e71.
42. Joseph P, Severe P, Ferdinand S, et al. Multidrug-resistant tuberculosis at an HIV testing center in Haiti. AIDS. 2006;20:415-418.
43. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2010.
44. Fox MP, Larson B, Rosen S. Defining retention and attrition in preantiretroviral HIV care: proposals based on experience in Africa. Trop Med Int Health. 2012;17:1235-1244.
45. Moon TD, Burlison JR, Blevins M, et al. Enrolment and programmatic trends and predictors of antiretroviral therapy initiation from president's emergency plan for AIDS Relief (PEPFAR)-supported public HIV care and treatment sites in rural Mozambique. Int J STD AIDS. 2011;22:621-627.
46. Orrell C. Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep. 2005;2:171-176.
47. Wringe A, Roura M, Urassa M, et al. Doubts, denial and divine intervention: understanding delayed attendance and poor retention rates at a HIV treatment programme in rural Tanzania. AIDS Care. 2009;21:632-637.
48. Nsigaye R, Wringe A, Roura M, et al. From HIV diagnosis to treatment: evaluation of a referral system to promote and monitor access to antiretroviral therapy in rural Tanzania. J Int AIDS Soc. 2009;12:31.
49. Bassett IV, Giddy J, Nkera J, et al. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007;46:181-186.
50. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7:234-244.
51. Mitchell SK, Kelly KJ, Potgieter FE, et al. Assessing social preparedness for antiretroviral therapy in a generalized AIDS epidemic: a diffusion of innovations approach. AIDS Behav. 2009;13:76-84.
52. Jarvis JN, Meintjes G, Wood R, et al. Testing but not treating: missed opportunities and lost lives in the South African antiretroviral therapy programme. AIDS. 2010;24:1233-1235.
53. Marcellin F, Abe C, Loubiere S, et al. Delayed first consultation after diagnosis of HIV infection in Cameroon. AIDS. 2009;23:1015-1019.
54. Guthrie BL, Choi RY, Liu AY, et al. Barriers to antiretroviral initiation in HIV-1-discordant couples. J Acquir Immune Defic Syndr. 2011;58:e87-e93.
55. Unge C, Johansson A, Zachariah R, et al. Reasons for unsatisfactory acceptance of antiretroviral treatment in the urban Kibera slum, Kenya. AIDS Care. 2008;20:146-149.
56. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
57. Bussmann H, Wester CW, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008;22:2303-2311.
58. Auld AF, Mbofana F, Shiraishi RW, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6:e18453.
59. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20:1181-1189.
60. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(suppl 1):1-15.
61. Leger P, Charles M, Severe P, et al. 5-Year survival of patients with AIDS receiving antiretroviral therapy in Haiti. N Engl J Med 2009;361: 828-829.
62. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007;4:e298.
63. Ochieng-Ooko V, Ochieng D, Sidle JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88:681-688.
64. Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005;353:2325-2334.
65. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl JMed. 2010;363:257-265.
66. Ferguson L, Grant AD, Watson-Jones D, et al. Linking women who test HIV-positive in pregnancy-related services to long-term HIV care and treatment services: a systematic review. Trop Med Int Health. 2012;17:564-580.
67. World Health Organization. Programmatic Update: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants-Executive Summary. Geneva, Switzerland: World Health Organization; 2012.
68. Charles M, Noel F, Leger P, et al. Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ. 2008; 86:970-977.
69. Flynn PM, Rudy BJ, Douglas SD, et al. Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy. J Infect Dis. 2004;190:271-279.
70. Murphy DA, Belzer M, Durako SJ, et al. Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med 2005;159:764-770.
71. Bertrand R, Edmond C, Jean-Paul K, et al. Adolescents, a population with special needs: the GHESKIO experience. In: Caribbean HIV Conference; November 18-21, 2011; Nassau, Bahamas. Abstract 2911.